BCL2 and acute myeloid leukemia: sorafenib reverses the activation of p90RSK and the inactivation of GSK3β, blocks the increase of MCL-1, and maintains the decrease of BCL-2 level, thus enhancing apoptosis in non-APL AML cell lines (Wang et al., 2016).